Please note that slides are for review only and not to be repurposed or published.

Leveraging the Immune System for Therapeutic Benefit in Non-Small Cell Lung Cancer: Scientific Insights, Clinical Applications and Future Directions

Introduction:
Dr Love

MODULE 1:
Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Langer

MODULE 2:
Incidence, Recognition and Management of Immune-Mediated and Other Toxicities with the Use of Anti-PD-1/PD-L1 Antibodies for Locally Advanced and Metastatic Disease — Dr Papadimitrakopoulou

MODULE 3:
Current Application of Immune Checkpoint Inhibitors in the Treatment of Metastatic NSCLC; Role for Patients with Actionable Tumor Mutations — Dr Spigel

MODULE 4:
Future Directions for Clinical and Translational Research — Dr Rizvi

Live Poll Results
Download

PARP Inhibition in Four Common Cancers: Biology, Clinical Research Database and Therapeutic Strategy

Introduction:
Dr Love

MODULE 1:
PARP Inhibition as a Therapeutic Strategy — Ovarian Cancer (OC) at the Vanguard — Dr Moore

MODULE 2:
Current and Emerging Role of PARP Inhibitors in Metastatic Breast Cancer (mBC) — Dr Telli

MODULE 3:
Pancreatic Cancer and PARP Inhibition — What We Know and What We Don’t — Dr Pishvaian

MODULE 4:
DNA Repair Deficiency in Advanced Prostate Cancer and the Potential Role of PARP Inhibition — Dr Antonarakis

Live Poll Results
Download